+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Direct Acting Antivirals Market - Global Forecast 2025-2030- Product Image
Direct Acting Antivirals Market - Global Forecast 2025-2030- Product Image
Sale

Direct Acting Antivirals Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6127542
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Direct acting antivirals have fundamentally evolved chronic viral infection management through precision therapies and accelerated treatment access. Senior leaders across the pharmaceutical value chain now face a dynamic market, demanding strategic alignment in R&D, supply chain adaptation, and resilient business models to secure competitive advantage.

Market Snapshot: Direct Acting Antiviral Market Overview

The direct acting antiviral market has experienced a robust transformation, driven by innovation in targeted therapies and shifting global healthcare policies. Adoption rates continue to climb, catalyzed by streamlined regulatory frameworks and the continued expansion of patient-centric care models. Regional differences persist, with established healthcare infrastructure in the Americas fostering early uptake and diverse models emerging across EMEA and Asia-Pacific. This evolving landscape offers promising opportunities for differentiation, as pharmaceutical leaders seek to address both access and scalability.

Scope & Segmentation: Comprehensive Insights Across Direct Acting Antivirals

  • Drug Classes: Includes NS3/4A protease inhibitors (such as glecaprevir and voxilaprevir), NS5A inhibitors (like ledipasvir sofosbuvir and velpatasvir sofosbuvir), and NS5B polymerase inhibitors (including dasabuvir and sofosbuvir).
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy channels shape patient purchasing behaviors and operational models.
  • End Users: Hospitals, retail pharmacies, and specialty clinics represent key points of care and product adoption.
  • Routes of Administration: Fixed dose combinations and single agent tablets, available in both once daily and twice daily dosing options, empower tailored care pathways.
  • Treatment Regimens: Combination therapies (dual and triple regimens) and monotherapies, covering varying inhibitor class pairings for clinical flexibility.
  • Geographic Regions: Coverage extends to Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, United Arab Emirates), and Asia-Pacific (China, India, Japan, Australia, South Korea, and more).
  • Company Landscape: Features profiles and trend analyses for Gilead Sciences, Inc., AbbVie Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Roche Holding AG, Johnson & Johnson, Viatris Inc., Cipla Limited, Natco Pharma Limited, and Hetero Labs Limited.

Key Takeaways for Senior Decision-Makers

  • Direct acting antivirals have enabled a fundamental shift in viral disease treatment, driving adoption of precision medicine and reshaping payer expectations around value and outcomes.
  • Regulatory acceleration and evolving reimbursement models prompt manufacturers to pursue innovative contracting approaches and strategic alliances with healthcare stakeholders.
  • Technological advancements, such as telemedicine platforms and digital therapeutics, are extending patient engagement capabilities, supporting adherence, and generating real-world evidence for further optimization.
  • Resilience in supply chain operations is increasingly critical, as manufacturers balance risk mitigation with the need for agile, scalable infrastructure across global markets.
  • Investment in next-generation compounds and flexible manufacturing processes positions organizations to address antiviral resistance and cost pressures amid evolving trade dynamics.

Tariff Impact: 2025 Supply Chain and Pricing Shifts

With the onset of targeted tariffs in 2025, input costs for direct acting antivirals face upward pressure, particularly for active pharmaceutical ingredients sourced from major chemical hubs. This shift compels manufacturers to diversify sourcing, implement dual-sourcing contracts, and consider near-shoring essential production processes. As a result, procurement strategies and pricing negotiations with payers are evolving, alongside investments in innovative, cost-reducing manufacturing technologies and cross-border partnerships to ensure sustained patient access amidst new regulatory environments.

Methodology & Data Sources

This report employs a mixed-method approach, integrating primary interviews with industry leaders, payers, and clinical experts to capture diverse perspectives. Secondary sources include peer-reviewed literature, regulatory filings, and industry reports for comprehensive validation. Cross-referencing and iterative stakeholder feedback sessions further enhance the robustness and integrity of the insights provided.

Why This Report Matters

  • Enables informed R&D investment and supply chain planning tailored to evolving trade and regulatory landscapes.
  • Supports strategic positioning based on regional market nuances, competitive benchmarking, and technology adoption trends.
  • Empowers commercial teams to design partnerships and access strategies that address both emerging risks and long-term growth priorities.

Conclusion

Senior executives who act on evidence-based, forward-looking insights will be better equipped to capitalize on the evolving direct acting antiviral market. This report enables focused decision-making by illuminating key drivers, actionable trends, and strategies aligned to next-generation patient care and operational resilience.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Acceleration of next-generation DAA therapies targeting resistant hepatitis C virus strains
5.2. Integration of pan-genotypic direct acting antivirals into standard hepatitis C treatment guidelines
5.3. Market penetration of fixed-dose combination DAA regimens in emerging Asia-Pacific economies
5.4. Impact of real-world evidence on pricing and reimbursement decisions for novel DAAs
5.5. Development of long-acting injectable formulations to improve DAA patient adherence rates
5.6. Expansion of DAA indications to address hepatitis B coinfections and special patient populations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Direct Acting Antivirals Market, by Drug Class
8.1. Introduction
8.2. Ns3/4A Protease Inhibitors
8.2.1. Glecaprevir
8.2.2. Voxilaprevir
8.3. Ns5A Inhibitors
8.3.1. Ledipasvir Sofosbuvir
8.3.2. Velpatasvir Sofosbuvir
8.4. Ns5B Polymerase Inhibitors
8.4.1. Dasabuvir
8.4.2. Sofosbuvir
9. Direct Acting Antivirals Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Direct Acting Antivirals Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Retail Pharmacies
10.4. Specialty Clinics
11. Direct Acting Antivirals Market, by Route of Administration
11.1. Introduction
11.2. Fixed Dose Combinations
11.2.1. Once Daily Dosing
11.2.2. Twice Daily Dosing
11.3. Single Agent Tablets
11.3.1. Once Daily Dosing
11.3.2. Twice Daily Dosing
12. Direct Acting Antivirals Market, by Treatment Regimen
12.1. Introduction
12.2. Combination Therapy
12.2.1. Dual Therapy
12.2.1.1. Ns3 4A Ns5A
12.2.1.2. Ns5A Ns5B
12.2.2. Triple Therapy
12.2.2.1. Ns3/4A Ns5A Ns5B
12.3. Monotherapy
13. Americas Direct Acting Antivirals Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Direct Acting Antivirals Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Direct Acting Antivirals Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Gilead Sciences, Inc.
16.3.2. AbbVie Inc.
16.3.3. Merck & Co., Inc.
16.3.4. Bristol-Myers Squibb Company
16.3.5. Roche Holding AG
16.3.6. Johnson & Johnson
16.3.7. Viatris Inc.
16.3.8. Cipla Limited
16.3.9. Natco Pharma Limited
16.3.10. Hetero Labs Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DIRECT ACTING ANTIVIRALS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DIRECT ACTING ANTIVIRALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DIRECT ACTING ANTIVIRALS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DIRECT ACTING ANTIVIRALS MARKET: RESEARCHAI
FIGURE 26. DIRECT ACTING ANTIVIRALS MARKET: RESEARCHSTATISTICS
FIGURE 27. DIRECT ACTING ANTIVIRALS MARKET: RESEARCHCONTACTS
FIGURE 28. DIRECT ACTING ANTIVIRALS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DIRECT ACTING ANTIVIRALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY GLECAPREVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VOXILAPREVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY LEDIPASVIR SOFOSBUVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY VELPATASVIR SOFOSBUVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DASABUVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SOFOSBUVIR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ONCE DAILY DOSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TWICE DAILY DOSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3 4A NS5A, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A NS5B, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A NS5A NS5B, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A NS5A NS5B, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES DIRECT ACTING ANTIVIRALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 147. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 162. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 163. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 164. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 165. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 166. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 167. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 168. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 169. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 170. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 171. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 172. CANADA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 173. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 180. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 181. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 192. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 193. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 194. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 195. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 196. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 197. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5A INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY FIXED DOSE COMBINATIONS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY SINGLE AGENT TABLETS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DUAL THERAPY, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM DIRECT ACTING ANTIVIRALS MARKET SIZE, BY TRIPLE THERAPY, 2025-2030 (USD MILLION)
TABLE 305. GERMANY DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 306. GERMANY DIRECT ACTING ANTIVIRALS MARKET SIZE, BY DRUG CLASS,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Direct Acting Antivirals market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Johnson & Johnson
  • Viatris Inc.
  • Cipla Limited
  • Natco Pharma Limited
  • Hetero Labs Limited

Related Topics

Related Reports

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2025-2030 - Product Image

Antiviral Drugs for the Treatment of Hepatitis C Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 181 Pages
  • Global
From
Hepatitis Therapeutics Market - Global Forecast 2025-2030 - Product Image

Hepatitis Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Oral Antivirals - Global Strategic Business Report - Product Image

Oral Antivirals - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Antivirals Drug - Global Strategic Business Report - Product Image

Antivirals Drug - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.